Enhanced expression of the CCN family of secretory integrin-binding proteins correlates with many essential components of the cancerous state, including tumor cell adhesion, proliferation, invasion and migration. Consequently, CCN1 expression is elevated in various cancers, including breast cancer, and its expression directly correlates with poor patient prognosis. Using subtraction-hybridization, combined with induction of cancer cell terminal differentiation, we cloned SARI (suppressor of activator protein (AP)-1, regulated by interferon (IFN)), an IFN-b-inducible, potent tumor suppressor gene that exerts cancer-selective growth inhibitory effects. Forced expression of SARI using an adenovirus (Ad.SARI) inhibits AP-1 function and downregulates CCN1 expression in multiple cancer lineages, resulting in a profound inhibition in anchorage-independent cell growth and tumor cell invasion. Overexpression of SARI reduces CCN1-promoter activity through inhibition of AP-1 binding. Accordingly, SARI selectively blocks expression of the transformed state in rat embryo fibroblast cells that stably overexpress c-Jun. These results illustrate that SARI inhibits AP-1 transactivating factor binding to the ciselement of the CCN1 promoter, possibly through its interaction with c-Jun. Overall, SARI can directly inhibit CCN1-induced transformation by inhibiting the transcription of CCN1, as well as indirectly by inhibiting the expression of c-Jun (and hence blocking AP-1 activity). In these contexts, transformed cells 'addicted' to AP-1 activity are rendered susceptible to SARI-mediated inhibition of expression of the transformed phenotype.
Introduction
Breast cancer is the leading cause of newly diagnosed cancer in American women and it is estimated that 182 460 new cases of invasive breast cancer and an additional 62 280 new cases of in situ cancer were diagnosed in 2009 (Jemal et al., 2009) . Integrin activation has been shown to have a seminal role in the development and progression of breast cancer, which is achieved through intracellular signaling by the activation of downstream kinases such as MAPK (Taddei et al., 2003; Vellon et al., 2005) . Overexpression of CCN1 in breast cancer cells culminates in upregulation of MAPK and other cell-proliferation signals in an integrin avb3-dependent manner, thereby promoting cell survival and chemoresistance to therapeutic agents (Felding-Habermann et al., 2001; Menendez et al., 2005) . The CCN1 gene encodes a 42-kDa matricellular protein that belongs to the CCN gene family (Brigstock, 1999; Grotendorst et al., 2000) . The nomenclature derives from the three major genes of the family, CCN1/Cyr61; CCN2/CTGF (connective tissue growth factor); CCN3/NOV (nephroblastoma overexpressed); and CCN4-6/WISP1-3 (Wnt-inducible secreted proteins). CCNs are a conserved family of proteins containing an N-terminal signal peptide, with up to four functional domains that each share sequence similarities with other protein motifs (Bork, 1993) .
CCN1 is a secretory integrin-binding protein that regulates angiogenesis, cell adhesion, migration, proliferation, survival and apoptosis (Chen et al., 2001; Leu et al., 2004) . Alternatively, CCN1 has a complex role in tumorigenesis, showing divergent functions and expression profiles in cancers from different tissues (O'Kelly, 2005) . Increased expression of CCN1 occurs in several cancer indications, that is, human breast cancers, malignant gliomas, gastric adenocarcinomas and melanomas (Jiang et al., 2004; O'Kelly et al., 2008) . CCN1 protein is found at higher levels in breast cancer samples compared with adjacent nontumor tissue, and staining of CCN1 in tumors positively correlates with American Joint Committee on Cancer (AJCC) disease stages I-IV. Of additional significance, a strong association was also found between lymph node involvement and high CCN1 expression in patients with invasive breast cancer (Jiang et al., 2004) . Both in vitro and in vivo studies document that overexpression of CCN1 in breast cancer cells upregulates MAPK signaling in an integrin avb3-dependent manner Vellon et al., 2005; O'Kelly et al., 2008) . Overexpression of CCN1 in breast cancer cell lines promotes their cell growth, migration and in vivo angiogenesis (Xie et al., 2001; Tsai et al., 2002a) . In contrast, small interfering RNA-based gene silencing of CCN1 resulted in a nearly complete inhibition of migration and invasion of breast cancer cells toward stromal fibroblasts (Nguyen et al., 2006) . Downregulation of CCN1 by staurosporine in prostate cancer cells is associated with neuronal differentiation and suppression of malignancy (Shimizu et al., 2005) . In these multiple contexts, selective inhibition of CCN1 in cancer cells might increase the therapeutic efficacy of anticancer agents.
Using subtraction-hybridization, combined with induction of cancer cell terminal differentiation, our laboratory cloned SARI (suppressor of activator protein (AP)-1, regulated by interferon (IFN); Jiang and Fisher, 1993; Su et al., 2008) , a novel type I IFN-inducible early response gene. The SARI cDNA (NCBI accession number HM134154) consists of 2,140 bp and codes for a putative protein of 274 amino-acid residues with a predicted molecular mass of 29.4 kDa and a pI (Isoelectric point) of 7.2. The SARI gene is located in the long arm of chromosome 11, between 11q12 and 11q13. The gene consists of three exons, translation starts in exon 1 and the stop codon is located in exon 3. SARI expression is induced as early as 2 h after IFN-b treatment, suggesting a role as an early mediator of IFN-b action. Moreover, expression of SARI mRNA was detected in normal cells of diverse lineages, including melanocytes, astrocytes, pancreatic mesothelial cells and breast and prostate epithelial cells, whereas expression was not detected in multiple cancer cell lines of the same tissue origin, which confirmed its putative function as a tumor suppressor gene. Forced expression of SARI resulted in tumor-selective growth inhibition and induction of apoptosis in prostate cancer (DU-145), malignant glioma (H4) and metastatic melanoma (MeWo) cells, while sparing their respective normal counterparts, that is, P69, PHFA and FM516-SV . Although the precise molecular mechanism by which SARI induces tumor-suppressing activity requires further clarification, preliminary studies revealed that forced expression of SARI resulted in inhibition of DNA binding of activator protein (AP-1) complexes and, consequently, it selectively inhibited AP-1-dependent gene expression. On the basis of similarities in protein sequence (particularly in the basic region-leucine zipper (bZip) domain), SARI may be the human and Batf2 the mouse version of the basic ATF 2-like protein, in which the bZIP transcription factor dimerizes with Jun proteins to bind to AP1-DNA sites (Echlin et al., 2000; Williams et al., 2001) . Although there are certain similarities between these two BATF proteins relative to their bZIP domains, sequence alignment indicates only an B26% identity. Therefore, further studies are required to determine whether these two proteins share similar functions, including profound cancer-specific antitumor activity (SARI) or effects on T H 17 differentiation and maturation and expansion of immature NKT cells in the thymus (BATF) (Zullo et al., 2007; Schraml et al., 2009) . This paper explains an important link between SARI and CCN1 expression. SARI selectively suppresses CCN1 transcription and hence inhibits CCN1-induced anchorage-independent growth and invasion in breast cancer, malignant glioma and metastatic melanoma cells. SARI also blocks the downstream cell proliferation signals produced by CCN1 through inhibition of the activation of MAP kinase and PI3-AKT kinases. These results suggest that SARI mediates downregulation of CCN1 by inhibiting DNA binding of AP-1 complexes to the CCN1 promoter, thereby resulting in reduced promoter activity and consequently decreased CCN1 transcription. In these contexts, we have now uncovered a novel association between expression of SARI and regulation of cancer progression induced by CCN1, suggesting applications of SARI for therapeutic intervention in cancers that are addicted to AP-1 and its downstream targets for survival and expression of the transformed state.
Results

SARI inhibits CCN1-induced anchorage-independent growth and invasion in cancer cells
A direct relationship between CCN1 expression and increased cell growth, proliferation and invasion has been observed (O'Kelly et al., 2008) . Transient transfection with a CCN1 expression construct (driven by a constitutive cytomegalovirus promoter) enhanced anchorage-independent growth in both immortal normal and cancer cell lines from different lineages, including normal melanocyte/melanoma, normal primary human fetal astrocyte/malignant glioma, normal prostate epithelial/prostate carcinoma and normal human breast epithelial/breast carcinoma ( Figure 1a and Supplementary Figure S1A ). In contrast, infection with an adenovirus that expresses SARI (Ad.SARI) at a low dose (10 pfu/cell) inhibited agar growth in all tumor cell contexts. In addition, the ability of CCN1 to stimulate anchorage independence was also inhibited when cells were simultaneously infected with Ad.SARI (10 pfu/cell; Figure 1a ). Moreover, transient transfection of breast and prostate cancer cells with a small interfering RNA targeting c-Jun resulted in profound inhibition of CCN1-induced anchorage-independent agar growth ( Figure 1a ). We previously reported that SARI interacts with c-Jun and hence interferes with AP-1 activation, which contributes to its cancer-selective antitumor activity. These results suggest that CCN1-mediated enhanced cloning efficiency is indirectly inhibited by SARI. In addition, using a Matrigel invasion assay, overexpression of CCN1 enhanced invasion in both weakly aggressive (MDA-MB-453, breast carcinoma; WM35, radial growth-phase primary melanoma) and highly aggressive (MDA-MB-231, breast carcinoma; WM238, metastatic melanoma) cancer cells (Figures 1b and c) . As observed with anchorage-independent growth, infection with SARI reduced CCN1-induced invasive ability of both weakly and highly aggressive breast cancer and melanoma cells (Figures 1b and c) .
Forced expression of SARI downregulates CCN1 expression by inhibiting transcription Studies were conducted to investigate whether SARI directly inhibits CCN1-induced expression and transformation-associated properties. An earlier report documented that TPA could induce a robust expression of CCN1 (Tsai et al., 2002b Figure 1 Overexpression of SARI attenuates CCN1-induced anchorage-independent growth and invasion in various cancer lineages.
(a) The indicated cell types were transiently transfected with pcDNA3.1, pcDNA3.1-CCN1 or control vector pcDNA3.1 (10 mg per 10 6 cells). After 24 h incubation, the transfected cells were infected with Ad.SARI (10 pfu/cell) or Ad.vec and, 24 h after viral infection, cells were evaluated for anchorage-independent growth in soft agar. Colonies (40.1-mm) were counted 2 weeks after seeding. siRNA treatment was carried out as described in Materials and methods 24 h after pcDNA3.1CCN1 transfection. Inset: Expression of c-Jun in siRNA-treated MDA-MB-231 cells. EF-1a was used as the loading control. (b) Breast cancer cells, MDA-MB-453 and MDA-MB-231, were transfected with pcDNA3.1-CCN1 or control vector pcDNA3.1 (10 mg per 10 6 cells). After 24 h incubation, transfected cells were infected with Ad.SARI (10 pfu/cell) or Ad.vec and, 24 h after viral infection, cells were evaluated for invasion using Matrigel invasion assays as described in Materials and methods. (c) Radial growth-phase melanoma WM35 and vertical growth-phase melanoma WM238 were treated as described in b and invasion was determined by Matrigel invasion assays. All experiments were conducted at least three times, and data represent mean ± s.d. (*Po0.05 vs pcDNA3.1 þ Ad.vec).
observation, we first determined expression of CCN1 in the presence of SARI at a transcriptional and translational level after treatment with 12-0-tetradecanoylphorbol-13-acetate (TPA). Infection with a low dose of Ad.SARI (20 pfu/cell) inhibited baseline and TPAinduced CCN1 expression both at an mRNA and protein level in human melanomas, malignant gliomas and breast cancer cells (Figures 2a and b) . Using nuclear run-on assays to measure the rate of new primary transcript formation, overexpression of SARI inhibited the transcription of CCN1 message (mRNA) in a timedependent manner, evident as early as 12 h after infection with Ad.SARI ( Figure 2c ; data shown for breast cancer, melanoma and malignant glioma cell lines, similar results were obtained in prostate cancer cells, data not shown). After infection with Ad.SARI (20 pfu/cell), significant suppression of CCN1 protein expression was observed in a temporal manner in all cancer cell lines, with complete extinction of CCN1 protein expression in specific cancer or transformed cell lines by 24-48 h (Figure 2d ; data for melanocyte and melanomas shown in Supplementary Figure S1B) . Similarly, a time-dependent inhibition in CCN1 mRNA expression was observed after infection with Ad.SARI (data not shown).
SARI attenuates CCN1 transformation-associated properties by inhibiting CCN1 expression and its downstream genes in breast cancer cells
To further investigate the role of SARI in modulating CCN1 expression, we generated stable MCF-7 breast carcinoma clones constitutively expressing elevated levels of CCN1 driven by a cytomegalovirus promoter ( Figure 3 ). MCF-7 cells were used for these studies because they express low levels of CCN1 endogenously as compared with other breast carcinomas ( For quantitative mRNA detection, total RNA was purified, blotted onto a nylon membrane and northern blotting was performed with a CCN1 and SARI cDNA probe. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression was used as a loading control. For detection of protein expression, wholecell lysates were collected and 50 mg of total protein for each sample was run on SDS-PAGE, transferred onto a nitrocellulose membrane and stained with anti-SARI and anti-CCN1 antibodies as described in Materials and methods; the indicated protein expression was determined by western blot analysis. EF-1a was used as a loading control. (b) WM35 and WM238 cells were treated as mentioned in a; quantitative mRNA expression of the indicated genes was detected by northern analysis and relative protein expression was detected by western analysis. (c) MDA-MB-231, WM238 and H4 cells were infected with Ad.vec or Ad.SARI at 10 pfu/cell and the nuclei were prepared from the treated cells at the indicated time. The isolated nuclei were used to label preinitiated RNA transcription with [a-32 P] UTP in vitro, and the purified RNA was hybridized to a dot blot carrying an equivalent amount of CCN1 cDNA probe. The transcription rate of GAPDH served as control. (d) The indicated cells were infected with Ad.vec or Ad.SARI at 20 pfu/cell. Protein lysates were collected at 0, 12, 24 and 48 h after Ad infection and expression of SARI and CCN1 was determined by western blot analysis as described in Materials and methods. EF-1a was used as a loading control. resulted in enhanced phosphorylation of ERK and Akt, which are established downstream targets of CCN1 (Figure 3a) . SARI expression inhibited the phosphorylation of ERK and AKT/PI3 kinases in both MCF-pcDNA3.1, MCF-CCN1 cl1 and MCF-CCN1 cl2 (Figure 3a ). CCN1 is a secreted protein and enhances MAPK and AKT/PI3 kinases through activation of integrins avb3 in breast cancer cells (Gery et al., 2005) . Overexpression of SARI enhanced anchorageindependent growth of MCF-7 cells (Figure 3c ) and their ability to invade through Matrigel (Figure 3d ). When infected with a low dose of Ad.SARI (20 pfu/cell), both anchorage independence in MCF-pcDNA3.1 and anchorage independence and invasion of MCF-CCN1 cl1 and MCF-CCN1 cl2 cells were inhibited (Figures 3c  and d ). In addition, transient transfection with siRNA (small interfering RNA) against c-Jun not only decreased CCN1 protein levels (Figure 3b ) in control and in CCN1-overexpressing MCF-7 clones but also inhibited CCN1-induced agar cloning (Figure 3c ) as observed with infection with Ad.SARI. Considering that CCN1 overexpression is driven by a constitutive promoter (cytomegalovirus), our data suggest the possibility of an additional indirect role of SARI in regulating CCN1-induced cell proliferation.
SARI eradicates CCN1-induced tumors generated by breast cancer cells in nude mice
Experiments were conducted to determine whether the in vitro effects of CCN1 and SARI could be recapitulated in vivo. To achieve this objective, MCF-7, MCF-CCN1 cl1 and MCF-CCN1 cl2 tumors were established in the flanks of athymic nude mice by injecting 1 Â 10 6 cells per animal. The MCF-7 tumors initially grew slowly but then disappeared within a week (data not shown). In contrast, MCF-CCN1 cl1 and MCF-CCN1 cl2 cells generated actively growing tumors. After palpable tumors of B100 mm 3 developed, in B7-10 days, the animals received seven intratumoral injections over a 4-week period with 1 Â 10 8 pfu per injection of Ad.vec or Ad.SARI. Both MCF-CCN1 cl1 and MCF-CCN1 cl2 cells formed large, aggressive and actively proliferating tumors in control (phosphate-buffered solution treated) or Ad.vec-infected animals, whereas Ad.SARI injections dramatically inhibited tumor growth, which was evident by 2 weeks after initiating therapy (Figures 4a and b) . We next compared the efficacy of Ad.SARI for in vivo transgene delivery and therapeutic activity by immunohistochemical staining for SARI protein, Ki-67 (which measures proliferation) and CD31 (which measures angiogenesis). In both MCF-CCN1 cl1 and MCF-CCN1 cl2 nude mice xenografts, infection with Ad.SARI resulted in significant SARI protein, which correlated with decreased expression of Ki-67 and CD-31 staining (Figure 4c ).
SARI inhibits CCN1 promoter function by interfering with AP-1 activation To elucidate the mechanism by which SARI inhibits CCN1 transcription, we initially evaluated CCN1 promoter activation as a function of forced expression of SARI in breast cancer, melanoma and malignant glioma in the presence or absence of TPA (Figure 5a ). Cells were transfected with CCN1/pGL3Luc (a fulllength CCN1 promoter cloned in the pGL3 basic vector), followed by infection with Ad.SARI (10 pfu/ cell). SARI inhibited both control and TPA-induced CCN1 promoter function within 24 h in all three-cancer indications (Figure 5a ). This activation and inhibition was reduced (Figure 5b ) when MDA-MB-231 cells were transfected with a CCN1(-AP-1)/pGL3Luc construct (a CCN1 promoter that lacks the AP-1 binding site). The overall luciferase activity of MDA-MB-231 cells transfected with CCN1(-AP1)/pGL3 without any treatment was lower as compared with cells transfected with CCN1/pGL3. These results indicate that maximal CCN1 promoter activity is dependent on AP-1 activation, and that SARI inhibition of CCN1 promoter function that lacks the AP-1 binding site is significantly reduced.
It is assumed that SARI may inhibit CCN1 promoter function by interfering with its AP-1 binding activity. Gel shift assays tested this hypothesis in all three-cancer indications using a consensus AP-1 probe. For gel shift assays, control (dimethyl sulfoxide) and TPA-treated cells were infected with Ad.SARI (20 pfu/cell) and, 24 h later, nuclear proteins were collected and assayed by Figure 4 Ad.SARI eradicates nude mouse xenograft tumors generated by stable transfectants of MCF-7 that ectopically overexpress CCN1. (a) Tumor xenografts were established by injecting MCF-CCN1 cl1 and MCF-CCN1 cl2 (MCF-7 clones stably overexpressing CCN1) in athymic nude mice, and tumors were injected with the indicated Ad over a 3-week period (total of seven injections). (a) Measurements of MCF-CCN1 cl1 and MCF-CCN1 cl2 xenograft tumor volumes. Points, average (with a minimum of five mice in each group); bars, ±s.d. Inset: photograph of the animals of each representative group. Control represents the uninfected mouse group. (b) Left, photograph of the MCF-CCN1 cl1 and MCF-CCN1 cl2 xenograft tumor at the end of the study; right, measurement of tumor weight at the end of the study. Columns, mean (with at least five mice in each group); bars, ± s.d. (c) Tumors were isolated from MCF-CCN1 cl1 and MCF-CCN1 cl2 xenografts after seven injections with the indicated Ad. Formalin-fixed, paraffin-embedded sections were immunostained for Ki-67, SARI and CD31. The detailed procedures for immunohistochemistry are described in Materials and methods.
SARI attenuates CCN1-mediated transformation R Dash et al electrophoretic mobility shift assay (EMSA). From Figure 5c , it is evident that in control (dimethyl sulfoxide) or TPA-treated samples, the level of AP-1 binding activity was markedly reduced after infection with Ad.SARI. This effect might result from SARImediated downregulation of basal or TPA-induced c-Jun expression ( Figure 5d ). As predicted from CCN1 mRNA and protein expression, baseline levels of AP-1 binding in immortal normal astrocytes (PHFA-Im), as well as in weakly aggressive melanoma (WM35) and breast carcinoma cells (MDA-MB-453), were lower than those in aggressive metastatic melanoma (MW238) and malignant glioma (H4) cells (Figure 5c ). To establish the identity and composition of these complexes, EMSAs were carried out using c-Jun polyclonal antibodies. Incubating nuclear extracts with the combination of anti-c-Jun resulted in the appearance of a supershifted band in TPA-treated WM238, which was inhibited by infection with Ad.SARI (Supplementary Figure S2A) .
A similar gel shift assay in WM238 cells using a consensus SP-1 probe did not show any reduced SP-1 binding activity in TPA-or Ad.SARI-treated groups (Supplementary Figure S2B) . SARI attenuates AP-1 transactivation of c-JUN binding to cis-elements in the CCN1 promoter As we demonstrate, SARI downregulates CCN1 promoter function by inhibiting AP-1 binding activity. We reported previously that SARI contains a leucine zipper motif that interacts with c-JUN, a potent transcription factor, and a leucine zipper containing AP-1 molecule . On the basis of this consideration, we reasoned that SARI interacts with c-JUN, resulting in inhibition of DNA binding of AP-1 to its recognition sequence in the CCN1 promoter. To validate this assumption, we measured CCN1 promoter activity in normal immortal cloned rat embryo fibroblast (CREF) The indicated cells were transfected with wild-type CCN1/pGL3Luc (10 mg per 10 6 cells) and, after 24 h incubation, transfected cells were infected with Ad.vec or Ad.SARI at 10 pfu/cell for another 24 h; luciferase assays were carried out as described in Materials and methods. TPA (100 ng/ml) was added 8 h before luciferse assays. (b) MDA-MB-231 cells were transfected with wild-type CCN1/pGL3Luc or AP-1 mutant CCN1 (-AP-1)/pGL3Luc (CCN1/pGL3Luc promoter that lacks AP-1 binding site) at a concentration of 10 mg per 10 6 cells. After 24 h incubation, the transfected cells were infected with Ad.vec or Ad.SARI at 10 pfu/cell for another 24 h and luciferase assays were performed as described in Materials and methods. TPA (100 ng/ml) was added 8 h before performing Luciferse assays. All experiments were conducted at least three times, and data represent mean±s.d. (*Po0.05). (c) The indicated cells were infected with Ad.vec or Ad.SARI at 20 pfu/cell for 24 h and then cells were treated with DMSO or TPA (100 ng/ml) for another 8 h. After the treatments, nuclear extracts were isolated and used for EMSA using a radiolabeled consensus AP-1 probe. The lane CC (cold competitor) represents the EMSA with a 100 Â unlabeled cold AP-1 oligonucleotide probe. (d) WM238 cells were infected with Ad.SARI or Ad.vec at 20 pfu/cell for a time period of 48 h and then cells were treated with DMSO or TPA (100 ng/ml) for another 8 h, after which cell lysates were collected. The expression of c-Jun was determined by western blot analysis as described in Materials and methods. EF-1a was used as a loading control. cells, and CREF-c-jun-13 and CREF-c-jun-16 (CREF clones stably overexpressing c-JUN protein) in the absence and presence of SARI (Figure 6a) . Infection with Ad.SARI inhibited CCN1 promoter activity in CREF-c-jun-13 and CREF-c-jun-16, but not in parental CREF cells (Figure 6a, left panel) . Similarly, infection with Ad.SARI exerted a profound inhibitory effect in the agar colony formation and invasive ability of CREF-c-jun-13 and CREF-c-jun-16 cells (Figure 6a , right panel and Figure 6b ). These effects might occur because Ad.SARI downregulates c-JUN, as well as CCN1 protein expression (Figure 6c) . Similarly, infection with Ad.SARI inhibited AP-1 binding to the CCN1 promoter in both CREF-c-jun-13 and CREF-c-jun-16 cells, which was evident from EMSA assays using a consensus AP-1 probe (Figure 6d ).
Discussion
Initiation of tumor formation and subsequent tumor progression culminating in migration to distant anatomic sites in the body is a complex multistep process controlled at several levels by both endogenous and exogenous factors, including oncogene activation, tumor suppressor gene inactivation, hormones and growth factors, as well as alterations in extracellular matrix composition (Roskelley and Bissell, 2002; Gery et al., 2005) . Many of these factors enhance CCN1 expression, implicating this gene as a potential nodal regulator of multiple stages of cancer progression in diverse cancer indications (Brigstock, 1999) . In this context, inhibition of CCN1 in cancer cells might provide a means of increasing the therapeutic efficacy of anticancer agents. In this study, we show that SARI, a potential tumor suppressor gene, inhibited CCN1-induced anchorageindependent growth and invasive ability by selectively downregulating CCN1 protein in a time-dependent manner in breast cancer, melanoma and malignant glioma cells. Furthermore, in vitro and in vivo studies document that SARI significantly inhibited the transformation-related properties of MCF-7 cells stably overexpressing CCN1. SARI also inhibited control (dimethyl sulfoxide) or TPA-induced CCN1 expression, preventing the activation of downstream proliferation signals of CCN1, that is, AKT/PI3 kinase and MAP kinase. Our data also confirm that SARI downregulates CCN1 at an mRNA level, supporting a transcriptional mechanism underlying the inhibitory effects of SARI. In total, SARI can inhibit CCN1-induced transformation directly by inhibiting the transcription of CCN1, as well as indirectly by inhibiting the expression of c-Jun (and hence blocking AP-1 activity; Figure 7) . AP-1 is a central component of many signal transduction pathways in a variety of cell types, and is critical for mitogenesis, apoptosis and carcinogenesis in a cell type-specific manner (Ludes-Meyers et al. AP-1 comprises a variety of dimeric bZIP proteins that belong to the Jun, Fos, Maf and ATF subfamilies (Chinenov and Kerppola, 2001) . Among the Jun proteins, c-Jun is the most potent transcriptional activator, and the c-Fos-c-Jun heterodimer positively regulates cell proliferation and transformation (Maki et al., 1987; Angel and Karin, 1991; Ryseck and Bravo, 1991) . Overexpression of c-Jun itself can immortalize rodent fibroblasts in culture (Vandel et al., 1996) . Augmented AP-1 activity has been observed in more than 90% of human cancers, indicating its seminal importance in human carcinogenesis (Eferl and Wagner, 2003) . TRANSFAC analysis (Wingender et al., 2000) revealed that the AP-1-like element in the Cyr61/CCN1 gene promoter is a variant of the AP-1 consensus sequence (base À821 to À828) in which a single-base substitution of the center nucleotide has occurred (5 0 -TGACTCAG-3 0 ). Earlier studies showed that the AP-1 element has a critical role in regulating CCN1 promoter activity and hence CCN1 expression is tightly regulated through AP-1 transcription factors (Han et al., 2003) . Mutation of the distal AP-1 element in the CCN1 promoter-reporter construct or overexpression of a dominant-negative AP-1 inhibitor reduced sphingosine 1-phosphate-induced CCN1 promoter activity by nearly 45% (Han et al., 2003) . We documented that SARI exerts a cancer-specific antitumor effect by inhibiting AP-1 binding activity . Whereas normal immortal CREF cells are resistant to SARI-induced growth inhibition, ras-and src-transformed CREF clones acquire sensitivity to SARI. Both ras-and srcsignaling induce c-Jun activation, indicating that cells that are 'addicted to AP-1' for proliferative advantage become susceptible to growth inhibition by SARI . To elucidate the manner in which SARI might inhibit AP-1 binding activity, we used CREF cells overexpressing c-Jun, an essential transcription factor for activation of AP-1 elements (Figure 6 ). Through sequence analysis of the SARI protein using InterPro Scan (http://www.ebi.ac.uk/interpro/), we identified a bZIP between 45 and 66 amino acid residues preceded by a highly basic region, suggesting that SARI might be a basic region-leucine zipper-containing transcription factor . However, SARI does not physically bind to the AP-1 complex. Interestingly, using a mammalian two-hybrid system, coimmunoprecipitation and immune fluorescence studies confirmed that the bZIP in SARI mediates its interaction with c-Jun. SARI, which is a nuclear protein, interacts with c-Jun in the nucleus and suppresses the DNA-binding activity of AP-1 complexes, thus inhibiting AP-1-mediated gene transcription . Furthermore, mutation of leucine 59 in the bZIP domain of SARI into proline completely abolished c-JUN and SARI interactions, indicating that the leucine zipper motif mediates the interaction between these proteins . On the basis of these considerations, we hypothesize that SARI interacts with c-JUN and hence interferes with AP-1 activation of the CCN1 promoter (Figure 7 ).
In conclusion, SARI, an ATF 2-like protein, shows potent tumor suppressor functions in a broad spectrum of human cancers. In this study, we document that a mechanism by which this gene exerts these profound effects in diverse human tumors, including breast cancer, malignant glioma and melanoma, is by targeting for suppression transcription of the CCN1 cancerpromoting gene and squelching c-JUN protein (preventing AP-1 activation). The CCN1 promoter is tightly regulated by AP-1 binding elements and SARI inhibits AP-1 binding activity by interacting with the transcription factor c-Jun (Figure 7) . Current studies are focused on identifying other potential interacting partners of SARI, that is, transcription factors such as E2F1 or CREB (cAMP response element-binding protein). As many common and sometimes unique transcription factors are overexpressed in cancer cells and, in particular contexts, growth and survival of tumor cells are inexorably linked to expression of specific transcription factors, SARI represents a potentially significant anticancer gene with broad antitumor potential .
Materials and methods
Cell lines and stable clones
Normal SV-40-immortalized human prostate epithelial cells (P69) and DU-145 and PC3 prostate carcinoma cells were cultured as described . Normal human spontaneously immortalized mammary epithelial cells such as HBL-100 and MCF-7, T47D, MDA-MB-157, MDA-MB-231 and MDA-MB-453 human breast cancer cells were cultured as described (Su et al., 1998) . Normal human SV-40-immortal melanocytes FM516-SV and WM25, WM238 and MeWo melanoma cells were cultured as described (Lebedeva et al., 2002) . H-TERT-immortalized primary human fetal astrocytes (PHFA-Im), SV40-T-antigen, H-TERT and Ha-ras-immortalized adult human astrocytes (THR), U87MG, as well as H4 human malignant glioma cell lines, were cultured as described . CREF and CREF clones stably overexpressing c-jun were cultured as described . The CCN1 expression plasmid in the backbone of pcDNA3.1/ Hygro( þ ) was constructed, followed by cloning of the CCN1 open reading frame using approaches described in Su et al. (2001) . MCF-7 ectopically expressing CCN1 clones were generated as described .
Construction of adenoviruses and plasmids
Total RNA was isolated from TPA-induced MCF-7 cells using a Qiagen mini-spin (Qiagen, San Diego, CA, USA) kit. The cDNAs were synthesized by reverse transcription-PCR using a cDNA synthesis kit (Invitrogen, San Diego, CA, USA); CCN1 ORF was amplified using primers 5 0 GCG CCACAATGAGCTCCCGCAT 0 3 (SN) and 5 0 TAGTCCCTA AATTTGTGAATGTC 0 3 (AS) and cloned into pCR2.1 TOPO TA cloning vector (Invitrogen). The CCN1 promoter (B1 kb fragment) was cloned by amplifying the genomic DNA isolated from PHFA-Im using primers 5 0 TCCAAAAACA AACAAGTACAACAT 0 3 (SN) and 5 0 GCTCTTTCGCTCG AGGTCCCG 0 3 (AS). The Cyr61/CCN1 promoter construct was cloned into the chloramphenicol acetyltransferase reporter vector pGL3 basic (Promega, Madison, WI, USA) to produce the CCN1/pGL3 construct. The AP-1-deleted CCN1 promoter construct CCN1(-AP1)/pGL3 (700 bp) was obtained by restriction digestion of pGL3/CCN1 by Kpn1 and Sma1, followed by amplification with T4 DNA polymerase, to fill the sticky end created by Kpn1; thereafter, blunt end ligation was performed to obtain CCN1(-AP1)/pGL3. An adenovirus lacking a gene insert in the E1 position, referred to as Ad.vec, and an adenovirus expressing SARI driven by the cytomegalovirus promoter in the E1 region (Ad.SARI) have been described elsewhere .
Nuclear run-on assays Nuclear run-on assays for CCN1 and glyceraldehyde 3-phosphate dehydrogenase were performed as described .
Preparation of whole-cell lysates and western blotting Western blotting was performed as previously described (Su et al., 2001) . The primary antibodies used were anti-SARI polyclonal antibody raised by immunizing rabbits with fulllength bacterially expressed SARI protein, anti-CCN1, anti-ERK, anti-p-ERK, anti-AKT and anti-p-AKT (Cell Signaling Technology, Danvers, MA, USA), anti c-Jun (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-EF1a (Upstate Biotechnology, Waltham, MA, USA).
RNA extraction, northern blot analysis Total cellular RNA isolation and northern blotting were performed as described (Su et al., 2001) . The cDNA probes were full-length human SARI, CCN1 and c-Jun, and glyceraldehyde 3-phosphate dehydrogenase.
Transient transfections and luciferase assays
Transient transfections and luciferase assays were performed using Lipofectamine 2000 (Invitrogen) as described (Su et al., 2001) . For luciferase assays, cells were transiently cotransfected with reporter gene constructs (CCN1/pGL3Luc) or with the pGL3-basic empty vector (Promega) and pRL-TK-luc plasmid coding for Renilla luciferase. Cells were incubated for 24 h and then treated with Ad.vec or Ad.SARI for the indicated time, after which the activity of firefly and Renilla luciferases was measured using the Dual-Luciferase reporter assay system (Promega). Control small interfering RNA and c-Jun small interfering RNA (Dharmacon RNAi Technology, Chicago, IL, USA) were transiently transfected into indicated cells for 24 h, after which cells were evaluated for anchorageindependent growth or western blot analysis.
EMSA Nuclear extracts were prepared from 2 to 5 Â 10 8 cells and EMSA was performed using a consensus AP-1 and SP-1 probe (Santa Cruz Biotechnology) as described (Su et al., 2001) .
Nude mice xenograft studies and immunohistochemical analysis MCF-7, MCF-CCN1 cl1 and MCF-CCN1 cl2 cells (1 Â 10 6 ) were injected subcutaneous (s.c.) in 100 ml of phosphate-buffered solution into the left flank of male athymic nude mice (NCRnu/nu, 4 weeks old, 20 gm body weight) as described previously (Sarkar et al., 2005) . After establishing visible tumors of B75 mm 3 , requiring B8-10 days, intratumoral injections with phosphatebuffered solution or different adenoviruses (Ad.vec and Ad.SARI) were administered at a dose of 4.5 Â 10 8 plaque-forming units in 100 ml. The injections were given 3X the first week and then twice a week for two more weeks for a total of seven injections. Tumor volume was measured twice weekly with a caliper and calculated using the formula p/6 Â larger diameter Â (smaller diameter) 2 . At the end of the experiment, the animals were killed and tumors were removed and weighed. Formalin-fixed tumors were sectioned and immunohistochemistry was performed as described (Dash et al., 2010) for detection of SARI, Ki-67 (BD Pharmingen, San Diego, CA, USA) and CD31 (Dako Corporation, California, USA).
Invasion assay and anchorage-independent growth assay in soft agar Invasion assays and anchorage-independent growth assay in soft agar assays were carried out as described .
Statistical analysis
Statistical analysis was carried out using one-way analysis of variance, followed by Fisher's protected least significant difference analysis. Po0.05 was considered significant.
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